Compare FUSB & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUSB | CYPH |
|---|---|---|
| Founded | 1952 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 73.4M |
| IPO Year | 1995 | N/A |
| Metric | FUSB | CYPH |
|---|---|---|
| Price | $16.75 | $0.63 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.3K | ★ 6.3M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $49.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.47 | $0.49 |
| 52 Week High | $16.50 | $3.70 |
| Indicator | FUSB | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 60.91 | 39.95 |
| Support Level | $15.75 | $0.54 |
| Resistance Level | N/A | $0.81 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 100.00 | 20.44 |
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.